144 related articles for article (PubMed ID: 35700590)
1. Viral eradication by direct-acting antivirals does not decrease the serum myostatin level in patients infected with hepatitis C virus.
Endo K; Sato T; Yoshida Y; Kakisaka K; Miyasaka A; Takikawa Y
Nutrition; 2022 Sep; 101():111699. PubMed ID: 35700590
[TBL] [Abstract][Full Text] [Related]
2. Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients.
Laguno M; Martínez-Rebollar M; Casanova M; de Lazzari E; González-Cordón A; Torres B; Inciarte A; Mora L; Ugarte A; Ambrosioni J; Blanco JL; Martínez E; Mallolas J
Clin Microbiol Infect; 2022 Apr; 28(4):610.e1-610.e7. PubMed ID: 34464735
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals.
Fouad R; Elsharkawy A; Abdel Alem S; El Kassas M; Alboraie M; Sweedy A; Afify S; Abdellatif Z; Khairy M; Esmat G
Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1129-1134. PubMed ID: 30896550
[TBL] [Abstract][Full Text] [Related]
4. Serum Galectin-3 in Hepatitis C Virus Infection Declines after Successful Virus Eradication by Direct-Acting Antiviral Therapy.
Weigand K; Peschel G; Grimm J; Müller M; Buechler C
J Gastrointestin Liver Dis; 2022 Dec; 31(4):444-452. PubMed ID: 36535063
[TBL] [Abstract][Full Text] [Related]
5. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.
Tada T; Kumada T; Toyoda H; Sone Y; Takeshima K; Ogawa S; Goto T; Wakahata A; Nakashima M; Nakamuta M; Tanaka J
Aliment Pharmacol Ther; 2018 Apr; 47(7):1012-1022. PubMed ID: 29424449
[TBL] [Abstract][Full Text] [Related]
6. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
[TBL] [Abstract][Full Text] [Related]
7. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
[TBL] [Abstract][Full Text] [Related]
8. Effect of Direct-Acting Antiviral Agents on Gastroesophageal Varices in Patients with Hepatitis C Virus-Related Cirrhosis.
Hisanaga H; Takedatsu H; Emori K; Inoue H; Kunitake Y; Nakane T; Fukunaga S; Ide T; Mitsuyama K; Torimura T
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013545
[TBL] [Abstract][Full Text] [Related]
9. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
10. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
[TBL] [Abstract][Full Text] [Related]
11. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Kobayashi N; Iijima H; Tada T; Kumada T; Yoshida M; Aoki T; Nishimura T; Nakano C; Takata R; Yoh K; Ishii A; Takashima T; Sakai Y; Aizawa N; Nishikawa H; Ikeda N; Iwata Y; Enomoto H; Hirota S; Fujimoto J; Nishiguchi S
Eur J Gastroenterol Hepatol; 2018 May; 30(5):546-551. PubMed ID: 29494353
[TBL] [Abstract][Full Text] [Related]
12. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
J Viral Hepat; 2021 Sep; 28(9):1284-1292. PubMed ID: 34105867
[TBL] [Abstract][Full Text] [Related]
13. Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis.
Sakamori R; Yamada R; Shinkai K; Doi A; Tahata Y; Shigekawa M; Kodama T; Hikita H; Yamada T; Tatsumi T; Takehara T
Intern Med; 2021; 60(5):745-750. PubMed ID: 33642562
[TBL] [Abstract][Full Text] [Related]
14. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
[TBL] [Abstract][Full Text] [Related]
15. Gender-Specific Differences in Serum Sphingomyelin Species in Patients with Hepatitis C Virus Infection-Sphingomyelin Species Are Related to the Model of End-Stage Liver Disease (MELD) Score in Male Patients.
Peschel G; Weigand K; Grimm J; Müller M; Krautbauer S; Höring M; Liebisch G; Buechler C
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176109
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
17. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
18. Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals.
Tajiri K; Okada K; Ito H; Kawai K; Kashii Y; Tokimitsu Y; Muraishi N; Murayama A; Hayashi Y; Minemura M; Takahara T; Shimizu Y; Yasuda I
BMC Gastroenterol; 2023 May; 23(1):182. PubMed ID: 37231349
[TBL] [Abstract][Full Text] [Related]
19. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
20. Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry.
Tacke F; Klinker H; Boeker KHW; Merle U; Link R; Buggisch P; Hüppe D; Cornberg M; Sarrazin C; Wedemeyer H; Berg T; Mauss S;
Hepatol Commun; 2022 Sep; 6(9):2488-2495. PubMed ID: 35666055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
